Proteostasis Therapeutics Inc (NASDAQ:PTI) stock rises 22% on FDA Designation, Smaller-Than-Expected Q4 Loss


Proteostasis Therapeutics Inc (NASDAQ:PTI) went up 22% in premarket trade on Thursday after the therapeutic company reported a less-than-expected loss for the fourth-quarter. The company further announced that the Food and Drug Administration had granted its cystic fibrosis drug orphan drug designation.

The Orphan drug designation grants the company seven years of exclusive marketing together with tax credits, federal grants and waived administrative filing fees. Additionally, the drug, PTI-428 was recently awarded the breakthrough therapy designation.

Earlier on Wednesday Proteostasis Therapeutics announced a loss of $13.4 million for the fourth quarter. This is below the $16.3 million which had been projected by FactSet consensus. In the results, the company reported $74.5 million in cash equivalents plus short-term investments. The company is optimistic that the available cash will be able to fund its expenses into early 2019. The company’s shares have gone up 31.4% in the last three months and reached $6.56. This is compared to the 2.8% rise in the S&P 500.

In other news, the company announced that it plans to offer and sell 9,000,000 shares of its common stock. This sell will be in an underwritten public offering that will be unveiled soon. This offering will be issued subject to market and other regulatory conditions. As part of the offering, the company plans give underwriters a 30-day option to buy up to an additional 1,350,000 shares which represents 15% of the common stock that will be offered in the public offering. All the shares that will be sold in the offering will be sold by Proteostasis.

The company has appointed RBC Capital Markets and Leerink Partners to act as joint book-running managers for the share offering. The company has appointed H.C. Wainwright & Co. to act as the lead manager for the offering. The offering will be implemented subject to fulfillment of market conditions. There is no assurance of when the offering will close. There are also no details on the real size and terms of the offering.

Proteostasis Therapeutics is a clinical stage biopharmaceutical company which is mainly dedicated to discovery and development of therapies used in treating cystic fibrosis (CF) plus other diseases which are caused by dysfunctional processing of protein.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.